All news

Long-term impact of imatinib on metastatic gastrointestinal stromal tumours (GIST)

03/04/2017 The EORTC 62005 study, recently published in Journal of Clinical Oncology demonstrated that patients with metastatic GIST continue to benefit from imatinib, a targeted therapy, with 13% of patients reported to be alive 10 years from starting treatment. It also confirmed that genomics might help pre...

Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200

Contact us

Follow us